297 related articles for article (PubMed ID: 33998168)
1. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
Subhi Y; Bjerager J; Boon CJF; van Dijk EHC
Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
[TBL] [Abstract][Full Text] [Related]
3. Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.
van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF
Am J Ophthalmol; 2019 Sep; 205():1-10. PubMed ID: 30951686
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
[TBL] [Abstract][Full Text] [Related]
5. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.
van Dijk EHC; Fauser S; Breukink MB; Blanco-Garavito R; Groenewoud JMM; Keunen JEE; Peters PJH; Dijkman G; Souied EH; MacLaren RE; Querques G; Downes SM; Hoyng CB; Boon CJF
Ophthalmology; 2018 Oct; 125(10):1547-1555. PubMed ID: 29776672
[TBL] [Abstract][Full Text] [Related]
6. Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial.
van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; MacLaren RE; Downes SM; Fauser S; Boon CJF; Hoyng CB
Am J Ophthalmol; 2020 Aug; 216():80-89. PubMed ID: 32289294
[TBL] [Abstract][Full Text] [Related]
7. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
[TBL] [Abstract][Full Text] [Related]
8. Comparing Half-Dose Photodynamic Therapy with Subthreshold Micropulse Laser for the Treatment of Central Serous Chorioretinopathy.
Brelen ME; Ho M; Li S; Ng DSC; Yip YWY; Lee WS; Chen LJ; Young AL; Tham CC; Pang CP
Ophthalmol Retina; 2024 May; 8(5):490-498. PubMed ID: 37956794
[TBL] [Abstract][Full Text] [Related]
9. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY.
Hu J; Qu J; Li M; Sun G; Piao Z; Liang Z; Yao Y; Sadda S; Zhao M
Retina; 2021 Jan; 41(1):189-198. PubMed ID: 32343102
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
[TBL] [Abstract][Full Text] [Related]
11. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients.
Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF
Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085
[TBL] [Abstract][Full Text] [Related]
12. Fuji sign: Prevalence and predictive power to photodynamic therapy in chronic central serous chorioretinopathy.
Pérez-García P; Oribio-Quinto C; Gómez-Calleja V; Moreno-Morillo FJ; Burgos-Blasco B; Fernández-Vigo JI
Photodiagnosis Photodyn Ther; 2023 Jun; 42():103316. PubMed ID: 36746235
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy.
van Rijssen TJ; Singh SR; van Dijk EHC; Rasheed MA; Vupparaboina KK; Boon CJF; Chhablani J
Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1191-1197. PubMed ID: 32170365
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
Karasu B; Akbas YB; Aykut A; Celebi ARC
Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.
Li M; Qu J; Liang Z; Tang J; Hu J; Yao Y; Jin E; Li X; Zhao M
Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2175-2182. PubMed ID: 35024912
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Son BK; Kim K; Kim ES; Yu SY
Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
[TBL] [Abstract][Full Text] [Related]
17. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS
Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076
[TBL] [Abstract][Full Text] [Related]
18. Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy.
Sitnilska V; Schiller P; Krohne TU; Altay L
BMC Ophthalmol; 2024 Jan; 24(1):8. PubMed ID: 38178104
[TBL] [Abstract][Full Text] [Related]
19. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Kabadayi K
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
[TBL] [Abstract][Full Text] [Related]
20. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
Sheptulin V; Purtskhvanidze K; Roider J
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
